CSS
CCCC icon

Cubist Systematic Strategies’s C4 Therapeutics CCCC Stock Holding History

Cubist Systematic Strategies’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$308K Sell
138,657
-101,302
-42% -$243K ﹤0.01% 2490
2025
Q2 		$343K Buy
+239,959
New +$349K ﹤0.01% 2410
2025
Q1 		– Sell
-109,825
Closed -$395K – 2916
2024
Q4 		$395K Buy
109,825
+6,799
+7% +$33.8K ﹤0.01% 2280
2024
Q3 		$587K Sell
103,026
-457,933
-82% -$2.76M ﹤0.01% 2135
2024
Q2 		$2.59M Sell
560,959
-203,903
-27% -$1.22M 0.02% 1166
2024
Q1 		$6.25M Buy
764,862
+453,485
+146% +$3.51M 0.04% 822
2023
Q4 		$1.76M Buy
311,377
+243,230
+357% +$555K 0.01% 1629
2023
Q3 		$127K Sell
68,147
-177,055
-72% -$540K ﹤0.01% 2895
2023
Q2 		$674K Buy
245,202
+230,642
+1,584% +$741K ﹤0.01% 2209
2023
Q1 		$45.7K Sell
14,560
-30,540
-68% -$180K ﹤0.01% 3579
2022
Q4 		$266K Sell
45,100
-40,808
-48% -$338K ﹤0.01% 3430
2022
Q3 		$753K Sell
85,908
-35,310
-29% -$367K ﹤0.01% 2856
2022
Q2 		$914K Buy
121,218
+82,194
+211% +$723K 0.01% 2550
2022
Q1 		$947K Buy
39,024
+5,027
+15% +$122K 0.01% 2066
2021
Q4 		$1.09M Sell
33,997
-3,303
-9% -$131K 0.01% 1846
2021
Q3 		$1.67M Buy
37,300
+27,567
+283% +$1.18M 0.02% 1153
2021
Q2 		$368K Buy
+9,733
New +$349K ﹤0.01% 2205
2021
Q1 		– Sell
-19,994
Closed -$662K – 2844
2020
Q4 		$662K Buy
+19,994
New +$580K 0.01% 1622

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cubist Systematic Strategies's CCCC Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its C4 Therapeutics (CCCC) stake by 42% in Q3 2025, selling an estimated $243K and leaving 138,657 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #2490.

Cubist Systematic Strategies first reported a position in CCCC in Q4 2020 and has held it in 18 quarters since. The position peaked at $6.25M in Q1 2024. 97 funds tracked by Wall St. Rank hold CCCC as of Q3 2025.

  • Cubist Systematic Strategies held 138,657 shares of C4 Therapeutics worth $308K as of Q3 2025.
  • Cubist Systematic Strategies sold 101,302 C4 Therapeutics shares in Q3 2025, an estimated $243K.
  • C4 Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2490 holding.
  • Cubist Systematic Strategies first reported a position in C4 Therapeutics in Q4 2020 and has held it in 18 quarters since.
  • Cubist Systematic Strategies's C4 Therapeutics position peaked at $6.25M in Q1 2024.
  • 97 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.